This review summarizes data on the main approaches used for the search of biologically active compounds modulating the level and physiological activity of incretins. Currently two groups of drugs are used in clinical practice: they either replenish the deficit of incretins (glucagon-like peptide-1 receptor agonists) or inhibit the degradation processes (dipeptidyl peptidase 4 inhibitors). In addition, new groups of substances are actively searched. These include non-peptide agonists of glucagon-like peptide-1 receptors, agonists/antagonists of glucose-dependent insulinotropic peptide, the hybrid polypeptides based on glucagon-like peptide-1 and glucagon
Spasov A.A., Chepljaeva N.I. (2015) Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2. Biomeditsinskaya Khimiya, 61(4), 488-496.
Spasov A.A. et al. Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2 // Biomeditsinskaya Khimiya. - 2015. - V. 61. -N 4. - P. 488-496.
Spasov A.A. et al., "Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2." Biomeditsinskaya Khimiya 61.4 (2015): 488-496.
Spasov, A. A., Chepljaeva, N. I. (2015). Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2. Biomeditsinskaya Khimiya, 61(4), 488-496.
Frerker N., Raber K., Bode F., Skripuletz T., Nave H., Klemann C., Pabst R., Stephan M., Schade J., Brabant G. et al. (2009) Clin. Chem. Lab. Med., 47, 257-287. CrossRef Scholar google search
Sedo A., Duke-Cohan J. S., Balaziova E., Sedova L.R. (2005) Arthritis Res. Ther., 7(6), 253-269. CrossRef Scholar google search
Matthews J.E., Stewart M.W., De Boever E.H., Dobbins R.L., Hodge R.J., Walker S.E., Holland M.C., Bush M.A. (2008) J. Clin. Endocrinol. Metab., 93, 4810-4817. Scholar google search
Sebokova E., Bénardeau A., Sprecher U., Sewing S., Tobalina L., Migliorini C. (2010) Diabetes Obes. Metab., 12, 674-682. Scholar google search
Ratner R., Nauck M., Kapitza C., Asnaghi V., Boldrin M., Balena R. (2010) Diabet. Med., 27, 556-562. Scholar google search
Bergenstal R.M., Forti A., Chiasson J.L., Woloschak M., Boldrin M., Balena R. (2012) Diabetes Ther., 3(1), 13. Scholar google search
Eto T., Inoue S., Kadowaki T. (2012) Diabetes Obes. Metab., 14(11), 1040-1046. Scholar google search
Seewoodhary J., Bain S.C. (2011) Br. J. Gen. Pract., 61(582), 5-6. Scholar google search
Kshirsagar A.D., Aggarwal A.S., Harle U.N., Deshpande A.D. (2011) Diabetes Metab. Syndr., 5 (2), 105-112. Scholar google search
Claus T.H., Pan C.Q., Buxton J.M., Yang L., Reynolds J.C., Barucci N., Burns M., Ortiz A.A., Roczniak S., Livingston J.N., Clairmont K.B., Whelan J.P. (2007) J. Endocrinol., 192(2), 371-380. CrossRef Scholar google search
Claus T.H., Pan C.Q., Buxton J.M., Yang L., Reynolds J.C., Barucci N., Burns M., Ortiz A.A., Roczniak S., Livingston J.N., Clairmont K.B., Whelan J.P. (2006) J. Biol. Chem., 281(18), 12506-12515. Scholar google search
Tom I., Lee V., Dumas M., Madanat M., Ouyang J., Severs J., Andersen J., Buxton J.M., Whelan J.P., Pan C.Q. (2007) AAPS J., 9 (2), 227-234. Scholar google search
Mentlein R. (2009) Best Pract. Res. Clin. Endocrinol. Metab., 23(4), 443-452. Scholar google search
Irwin N., Flatt P.R. (2009) Best Pract. Res. Clin. Endocrinol. Metab., 23, 499-512. Scholar google search
Green B.D., Irwin N., Gault V.A. O'Harte F., Flatt P. (2005) Br. J. Diabetes Vasc. Dis., 5, 134-140. Scholar google search
Green B.D., Flatt P.R. (2007) Best Pract. Res. Clin. Endocrinol. Metab., 4(21), 497-516. Scholar google search
Tharakan G., Tan T., Bloom S. (2011) Trends Pharmacol. Sci., 32(1), 8-15. Scholar google search
Dhayal S., Morgan N.G. (2010) Drug News Perspect., 23(7), 418-424. Scholar google search
Overton H.A., Fyfe M.C.T., Reynet C. (2008) Br. J. Pharmacol., 153, S76-S81. Scholar google search
